In a retrospective study of a cohort of Italian patients using the same diagnostic antibody and criteria for CLDN18.2 positivity, a concordance rate of 81.5% was reported in pair-matched tumor samples from 27 patients collected from primary and metastatic sites [12]. Here, CLDN18 is linked to neoplasm.